Core Insights - Lucas GC Limited (NASDAQ:LGCL) reported strong financial results for the first half of 2025, with an EPS of $1.47 and sales of $54.008 million, leading to a 36.2% increase in share price to $3.73 in pre-market trading [1] Gainers - MSP Recovery, Inc. (NASDAQ:MSPR) saw a significant gain of 262% to $0.7706 in pre-market trading after a previous decline of 30% [5] - SMX (Security Matters) Public Limited Company (NASDAQ:SMX) surged 72% to $3.47 after a 17% drop on Friday [5] - Raytech Holding Limited (NASDAQ:RAY) rose 44.1% to $0.2378 following a 16-for-1 share consolidation [5] - MultiSensor AI Holdings, Inc. (NASDAQ:MSAI) increased by 30.1% to $2.02 after an 18% rise on Friday [5] - Caribou Biosciences, Inc. (NASDAQ:CRBU) gained 25.2% to $3.03 after a 4% increase on Friday [5] - Datavault AI Inc. (NASDAQ:DVLT) rose 21.5% to $2.47 after a 19% decline on Friday [5] - The Generation Essentials Group (NYSE:TGE) surged 8.2% to $0.87 after a 54% drop on Friday [5] - Modular Medical, Inc. (NASDAQ:MODD) gained 10.6% to $0.5486 in pre-market trading [5] - Apollomics, Inc. (NASDAQ:APLM) rose 9.6% to $15.31 after a 20% increase on Friday [5] Losers - ZOOZ Strategy Ltd (NASDAQ:ZOOZ) fell 28.3% to $1.01 after a 7% decline on Friday [5] - Alvotech (NASDAQ:ALVO) declined 21.6% to $6.00 after a 2% drop on Friday [5] - XORTX Therapeutics Inc. (NASDAQ:XRTX) fell 18% to $0.4940 in pre-market trading [5] - EpicQuest Education Group International Limited (NASDAQ:EEIQ) decreased by 17.5% to $0.3713 after filing for a mixed shelf offering of up to $75 million [5] - NewcelX Ltd. (NASDAQ:NCEL) shares dipped 15.2% to $6.18 after a 44% gain on Friday [5] - Beneficient (NASDAQ:BENF) dipped 13.4% to $0.7155 after a 48% increase on Friday [5] - EPWK Holdings Ltd. (NASDAQ:EPWK) fell 11.7% to $0.0755 after a 29% rise on Friday [5] - Taitron Components Incorporated (NASDAQ:TAIT) fell 11.5% to $2.12 in pre-market trading [5] - INVO Fertility, Inc. (NASDAQ:IVF) dipped 10.8% to $0.4820 after a 17% gain on Friday [5] - Top KingWin Ltd (NASDAQ:WAI) fell 9.8% to $3.22 after a 19% increase on Friday [5]

分组1 - Delcath Systems Inc reported a significant increase in share price, rising 14.2% to $13.66 in pre-market trading following the announcement of preliminary third quarter 2025 financial results [1] - The company's Phase 2 CHOPIN study achieved its primary endpoint, demonstrating that PHP plus immunotherapy extended median progression-free survival (PFS) to 12.8 months, compared to 8.3 months previously [1] 分组2 - Beyond Meat Inc saw a substantial gain of 76.6%, reaching $1.14 in pre-market trading after a 24% surge on the previous Friday [4] - FGI Industries Ltd experienced a 64.1% increase to $7.81 in pre-market trading [4] - Celcuity Inc surged 44.3% to $75.00 following the announcement of Phase 3 VIKTORIA-1 data [4] - Rani Therapeutics Holdings Inc's shares jumped 32.5% to $2.18 after a collaboration agreement with Chugai Pharmaceutical and an oversubscribed $60.3 million private placement [4] 分组3 - Exelixis Inc's shares fell 8.3% to $36.00 after announcing detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer [5]

Company Developments - Rani Therapeutics Holdings, Inc. (RANI) experienced a significant price increase of 303.48% to $1.9, attributed to a licensing agreement with Chugai Pharmaceutical potentially worth up to $1.09 billion, involving an oral drug and possibly extending to five drugs [1][7] - Artiva Biotherapeutics, Inc. (ARTV) saw a 148.74% rise to $6.89, linked to the FDA granting Fast Track Designation for its AlloNK® development targeting refractory rheumatoid arthritis, with promising trial results showing consistent B-cell depletion and favorable safety profiles [2][7] - Sunshine Biopharma, Inc. (SBFMW) had a 71.22% increase to $0.29, driven by investor optimism regarding potential breakthroughs in its anticancer research [3][7] - NextPlat Corp (NXPLW) rose by 55.52% to $0.1, possibly reflecting new contracts or technological advancements in mobile satellite services, with expansion into new markets impacting its business model and revenue streams [4] - XORTX Therapeutics Inc. (XRTX) experienced a 52.35% increase to $1.29, due to acquiring a renal anti-fibrotic therapeutic program from Vectus Biosystems, enhancing its clinical programs [5] Market Trends - Recent market trends indicate notable price changes among several companies, reflecting various factors driving investor interest, underscoring the dynamic nature of the stock market [6]

Core Viewpoint - XORTX Therapeutics Inc. has received notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its common shares have been below US$1.00 for 30 consecutive business days [1][2]. Group 1: Compliance Status - The notification does not currently impact the Company's listing on the Nasdaq Capital Market, and it has 180 calendar days to regain compliance [2]. - If the bid price closes at or above US$1.00 for at least 10 consecutive business days within this period, Nasdaq will notify the Company of compliance [2]. Group 2: Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for progressive kidney disease and gout, with three advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [4]. - The Company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [4].

Core Points - XORTX Therapeutics Inc. has received notification from Nasdaq that it is not in compliance with the minimum bid price requirement, as its common shares have closed below US$1.00 for 30 consecutive business days [1] - The company has 180 calendar days from the notification date to regain compliance, during which its shares will continue to trade on the Nasdaq Capital Market [2] - If the bid price closes at or above US$1.00 for at least 10 consecutive business days, Nasdaq will notify the company of compliance [2] - The notification does not affect the company's listing status on the TSX Venture Exchange [3] - XORTX is evaluating options to resolve the deficiency and regain compliance with Nasdaq Rule 5550(a)(2) [3] Company Overview - XORTX Therapeutics is focused on developing therapies for progressive kidney disease and gout, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [4] - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [4] - XORTX aims to improve the quality of life for individuals with gout and other diseases by targeting purine metabolism and xanthine oxidase to reduce uric acid production [4]